The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Dual-targeted CD19/CD20 CAR-T shows promising efficacy in relapsed/refractory CLL
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses findings from the Phase I LV20.19 study (NCT04186520) of a dual-targeted anti-CD20/anti-CD19 CAR-T cell therapy in relapsed/refractory chronic lymphocytic leukemia (CLL). He highlights the rationale for dual-antigen targeting, key safety observations that led to dose optimization, and the encouraging efficacy results, including high response rates and promising progression-free survival (PFS). This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
